Tangvoraphonkchai Kamonwan, Riddell Anne, Davenport Andrew
Department of Renal Medicine, Mahasarakham University Hospital, Mahasarakham, Thailand.
Haemophilia Centre & Thrombosis Unit, Royal Free Hospital, Pond Street, London NW3 2QG.
Hemodial Int. 2018 Apr;22(2):192-200. doi: 10.1111/hdi.12586. Epub 2017 Aug 1.
Hemodialysis patients are pro-thrombotic. Higher volume online postdilutional hemodiafiltration (OL-HDF), with increasing hematocrit increases the risk of clotting in the extracorporeal circuit (ECC). We wished to determine whether OL-HDF increased platelet activation and ECC clotting.
Coagulation parameters, platelet, white cell, and endothelial activation markers were measured at the start and end of dialysis sessions in 10 patients and also pre- and post-dialyzer after 15 minutes using two different dialyzers designed for high volume OL-HDF; cellulose triacetate (TAGP) and polysulphone (PS), and polyvinylpyrrolidone (PVP). Patients were anticoagulated with a heparin bolus.
At the start of OL-HDF, D dimers, thrombin antithrombin complexes (TATs), and soluble adhesions molecules (sICAM-1 and sVCAM-1) were increased. Post-treatment soluble P selectin (PS/PVP 26.7 ± 7.1 versus 36.6 ± 9.9; TAGP 28.7 ± 7.2 versus 43.5 ± 8.4 ng/ml, P < 0.001), and soluble CD40 ligand (PS/PVP 297 ± 228 versus 552 ± 272, TAGP 245 ± 187 versus 390 ± 205 ng/ml, P < 0.05) increased. Post-dialyzer concentrations increased versus pre-dialyzer for tissue factor (PS/PVP 117 ± 12 versus 136 ± 16, TAGP 100 ± 25 versus 128 ± 40 ng/ml, P < 0.05), factor VIIIc (PS/PVP 174 ± 54 versus 237 ± 83, TAGP 163 ± 60 versus 247 ± 102 IU/ml, P < 0.01), sVCAM-1 (PS/PVP 782 ± 64 versus 918 ± 140, TAGP 722 ± 121 versus 889 ± 168 ng/ml, P < 0.01), and D-dimers (PS/PVP 292 ± 132 versus 355 ± 167, TAGP 300 ± 129 versus 391 ± 171 ng/ml, P < 0.001). There was no macroscopic thrombus noted in the ECC, and no increase in microparticles, platelet factor-4, or TATs.
Despite being pro-thrombotic, with activation of platelets, and lymphocytes during passage through ECC, no macroscopic clotting, or increased TATs were noted during OL-HDF, and no major differences between cellulosic and polysulphone dialyzers.
血液透析患者具有血栓形成倾向。更高容量的在线后稀释血液透析滤过(OL-HDF)随着血细胞比容增加会增加体外循环(ECC)凝血风险。我们希望确定OL-HDF是否会增加血小板活化和ECC凝血。
使用两种专为高容量OL-HDF设计的不同透析器(三醋酸纤维素(TAGP)和聚砜(PS)以及聚乙烯吡咯烷酮(PVP)),在10例患者透析治疗开始和结束时以及15分钟后透析器前后测量凝血参数、血小板、白细胞和内皮细胞活化标志物。患者接受肝素推注抗凝。
在OL-HDF开始时,D-二聚体、凝血酶抗凝血酶复合物(TATs)和可溶性黏附分子(sICAM-1和sVCAM-1)升高。治疗后可溶性P选择素(PS/PVP 26.7±7.1对36.6±9.9;TAGP 28.7±7.2对43.5±8.4 ng/ml,P<0.001)和可溶性CD40配体(PS/PVP 297±228对552±272,TAGP 245±187对390±205 ng/ml,P<0.05)升高。透析器后组织因子(PS/PVP 117±12对136±16,TAGP 100±25对128±40 ng/ml,P<0.05)、因子VIIIc(PS/PVP 174±54对237±83,TAGP 163±60对247±102 IU/ml,P<0.01)、sVCAM-1(PS/PVP 782±64对918±140,TAGP 722±121对889±168 ng/ml,P<0.01)和D-二聚体(PS/PVP 292±132对355±167,TAGP 300±129对391±171 ng/ml,P<0.001)浓度相对于透析器前升高。ECC中未观察到肉眼可见的血栓,微粒、血小板因子4或TATs也未增加。
尽管具有血栓形成倾向,在通过ECC期间血小板和淋巴细胞被激活,但在OL-HDF期间未观察到肉眼可见的凝血或TATs增加,并且纤维素和聚砜透析器之间没有重大差异。